S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Pharming Group Stock Forecast, Price & News

0.00 (0.00%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
7,648 shs
Market Capitalization
$494.45 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PHGUF News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

Pharming Group logo

About Pharming Group

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Tobacco products
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$212.10 million
Cash Flow
$0.06 per share
Book Value
$0.27 per share


Net Income
$37.74 million
Pretax Margin




Free Float
Market Cap
$494.45 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

Is Pharming Group a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pharming Group stock.
View analyst ratings for Pharming Group
or view top-rated stocks.

How has Pharming Group's stock been impacted by Coronavirus?

Pharming Group's stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PHGUF shares have decreased by 41.5% and is now trading at $0.79.
View which stocks have been most impacted by COVID-19

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.01. Pharming Group had a net margin of 11.02% and a trailing twelve-month return on equity of 12.33%.
View Pharming Group's earnings history

What price target have analysts set for PHGUF?

1 brokerages have issued 1 year price objectives for Pharming Group's shares. Their forecasts range from $3.10 to $3.10. On average, they anticipate Pharming Group's stock price to reach $3.10 in the next year. This suggests a possible upside of 292.4% from the stock's current price.
View analysts' price targets for Pharming Group
or view top-rated stocks among Wall Street analysts.

Who are Pharming Group's key executives?

Pharming Group's management team includes the following people:
  • Sijmen de Vries, Chief Executive Officer & Executive Director
  • Mireille Sanders, Senior Vice President-Operations
  • Jeroen Henk Wakkerman, Chief Financial Officer
  • Robert Friesen, Chief Scientific Officer
  • Anurag Relan, Chief Medical Officer

Who are some of Pharming Group's key competitors?

What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $0.79.

How much money does Pharming Group make?

Pharming Group has a market capitalization of $494.45 million and generates $212.10 million in revenue each year. The biotechnology company earns $37.74 million in net income (profit) each year or $0.03 on an earnings per share basis.

How many employees does Pharming Group have?

Pharming Group employs 262 workers across the globe.

What is Pharming Group's official website?

The official website for Pharming Group is www.pharming.com.

Where are Pharming Group's headquarters?

Pharming Group is headquartered at Darwinweg 24, Leiden P7, 2333 CR.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at (171) 524-7400, via email at [email protected], or via fax at 31-0-71-524-7445.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.